Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research.
性状
Lyophilized Powder
IC50 & Target[1][2]
HIV-1
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785.